Photodynamic Therapy in Gastroenterology

Шишкова, Н.; Кузнецова, О. М.; Berezov, T. T.

doi:10.1007/s12029-013-9496-4

Cited by 39 publications

(35 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PS-based fluorescence imaging has shown promising results in the detection of ovarian cancer [116, 117], pancreatic cancer [118, 119] and lung cancer [120, 121]. …”

Section: Other Photosensitizersmentioning

confidence: 99%

Photosensitizers in prostate cancer therapy

2017

View full text Add to dashboard Cite

The search for new therapeutics for the treatment of prostate cancer is ongoing with a focus on the balance between the harms and benefits of treatment. New therapies are being constantly developed to offer treatments similar to radical therapies, with limited side effects. Photodynamic therapy (PDT) is a promising strategy in delivering focal treatment in primary as well as post radiotherapy prostate cancer. PDT involves activation of a photosensitizer (PS) by appropriate wavelength of light, generating transient levels of reactive oxygen species (ROS). Several photosensitizers have been developed with a focus on treating prostate cancer like mTHPC, motexafin lutetium, padoporfin and so on. This article will review newly developed photosensitizers under clinical trials for the treatment of prostate cancer, along with the potential advantages and disadvantages in delivering focal therapy.

show abstract

“…PS-based fluorescence imaging has shown promising results in the detection of ovarian cancer [116, 117], pancreatic cancer [118, 119] and lung cancer [120, 121]. …”

Section: Other Photosensitizersmentioning

confidence: 99%

Photosensitizers in prostate cancer therapy

2017

View full text Add to dashboard Cite

show abstract

“…In literature, there are some preclinical studies about the maintained organs' tumor. PDT with Pcs and PS of pancreatic cancer and colon tumor studies show that the results are encouraging toward future clinical applications of PDT for pancreatic cancer and colon tumor in literature (26)(27)(28)(29)(30)(31). Tzerkovsky et al (32) firstly reported on feasibility of efficient use of PDT with a PS of chlorin series and AAT with bevacizumab for the treatment of brain tumors in experimental models.…”

Section: Radiolabeling Resultsmentioning

confidence: 97%

Investigation of In vitro PDT Activities and In vivo Biopotential of Zinc Phthalocyanines Using ¹³¹I Radioisotope

Ince

Ocakoğlu

et al. 2015

Chem Biol Drug Des

View full text Add to dashboard Cite

Novel octylthio-containing asymmetrically substituted Zn(II) phthalocyanine (Zn(II)Pc1) and a symmetric derivative (Zn(II)Pc2) have been prepared to investigate the biological potential and ability to photosensitize singlet oxygen for photodynamic therapy applications. In this study, the singlet oxygen generation potential and in vitro photodynamic activities of these compounds have been tested. Both ZnPcs reveal to be very efficient singlet oxygen generators and promising PSs for PDT applications. In vitro PDT activities of the compounds were evaluated in EMT-6 murine mammary carcinoma and HeLa human cervix carcinoma cell lines. Moreover, Zn(II)Pc1 displayed the phototoxic effects in the mammary cancer cell line (6.25 μm concentration at 30 J/cm(2) light dose and 12.5 μm concentration at 20 J/cm(2) light dose), while Zn(II)Pc2 did not show any phototoxic effects both in two cell lines. Zn(II)Pcs were radiolabeled with (131) I in high yields. Biodistribution studies revealed that the radiolabeled Zn(II)Pc1 showed significant uptake in l. intestine, pancreas, brain, and ovary, while Zn(II)Pc2 has significant uptake in ovary and pancreas in normal rats. Hence, these Pcs derivatives could be promising candidate for tumor nuclear imaging.

show abstract

“…PDT uses a systemically administered photosensitizing drug, typically prophimer sodium (Ps) 4-aminolevulinic acid (ALA), or m-tetrahydroxyphenyl chlorine, which accumulates in tumor tissue and is then activated by endoscopically delivered laser light using an appropriate wavelength (59). Ps is the most commonly used sensitizer, and is typically given intravenously 2 days prior to the endoscopic procedure to allow time for adequate absorption into the tissue.…”

Section: Photodynamic Therapy (Pdt)mentioning

confidence: 99%

Barrett’s esophagus: best practices for treatment and post-treatment surveillance

Mansour

El–Serag

Anandasabapathy

2017

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

Barrett's esophagus (BE) is a premalignant condition that increases the risk of esophageal adenocarcinoma (EAC). Significantly more common in the Western world, risk factors include increased age, male sex, white race, gastro-esophageal reflux disease (GERD), central obesity, and cigarette smoking. The rates of progression to cancer depend on the grade of Barrett's dysplasia. Screening for BE is recommended in patients with GERD and additional risk factors. Endoscopic surveillance of patients with BE likely improves overall outcomes. Advanced endoscopic imaging can help increase the efficiency of current endoscopic surveillance.Endoscopic therapy is safe and effective for the treatment of dysplastic BE and intramucosal EAC, but ongoing surveillance following treatment is necessary. This review will cover screening, surveillance, advanced imaging, chemoprevention, endoscopic treatment, and post-treatment surveillance of BE.

show abstract

Photodynamic Therapy in Gastroenterology

Cited by 39 publications

References 99 publications

Photosensitizers in prostate cancer therapy

Photosensitizers in prostate cancer therapy

Investigation of In vitro PDT Activities and In vivo Biopotential of Zinc Phthalocyanines Using ¹³¹I Radioisotope

Barrett’s esophagus: best practices for treatment and post-treatment surveillance

Contact Info

Product

Resources

About

Photodynamic Therapy in Gastroenterology

Cited by 39 publications

References 99 publications

Photosensitizers in prostate cancer therapy

Photosensitizers in prostate cancer therapy

Investigation of In vitro PDT Activities and In vivo Biopotential of Zinc Phthalocyanines Using 131I Radioisotope

Barrett’s esophagus: best practices for treatment and post-treatment surveillance

Contact Info

Product

Resources

About

Investigation of In vitro PDT Activities and In vivo Biopotential of Zinc Phthalocyanines Using ¹³¹I Radioisotope